Value-based healthcare (VBHC) is gaining traction across the industry for its potential to improve patient care by standardising clinical and patient outcomes.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh